Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

The National Institute for Health and Care Excellence (Nice) is concerned about the number of people regaining weight after ...

Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...

I've been paying for Mounjaro for more than a year, and have lost a fair bit of weight. Now it's available on the NHS, will I ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight.

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

NYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the ...

The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...

Patients coming off Wegovy or Mounjaro should have support and advice for at least a year afterwards, NHS told.